p53 alterations in colon tumors: A comparison of SSCP/sequencing and immunohistochemistry

Applied Immunohistochemistry and Molecular Morphology

Volumn 12, Issue 4, 2004, Pages 380-386

  Curtin, Karen ^a   Slattery, Martha L ^a   Holubkov, Richard ^a   Edwards, Sandra ^a   Holden, Joseph A ^a   Samowitz, Wade S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Case control; Colon cancer; Immunohistochemistry; p53; Protein overexpression; Sequencing

Indexed keywords

DNA; PROTEIN P53; RAS PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; COLON CANCER; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENDER; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 10044243594     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200412000-00017     Document Type: Article

References (26)

1. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucl Acids Res. 1994;22:3551-3555.
2. Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346-355.
3. Freedman AN, Michalek AM, Marshall JR, et al. Familial and nutritional risk factors for p53 overexpression in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:285-291.
4. Slattery ML, Curtin K, Ma K, et al. Diet, activity, and lifestyle associations with p53 mutations in colon tumors. Cancer Epidemiol Biomarkers Prev. 2002;11:541-548.
5. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor-suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
6. Voskuil DW, Kampman E, van Kraats AA, et al. p53 over-expression and p53 mutations in colon carcinomas: relation to dietary risk factors. Int J Cancer. 1999;81:675-681.
7. Dix B, Robbins P, Carrello S, et al. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer. 1994;70:585-590.
8. Andersen TI. Bø'rresen A-L. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Diagn Mol Pathol. 1995;4:203-211.
9. Andersen TI, Holm R, Nesland JM, et al. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer. 1993;68:540-548.
10. Walker DR, Bond JR, Tarone RE, et al. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene. 1999;18:211-218.
11. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer - beyond physical activity. Cancer Res. 1997;57:75-80.
12. Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and Ki-ras and p53 gene alterations in colon cancer. Am J Pathol. 2001;158:1517-1524.
13. Slattery ML, Edwards S, Caan B, et al. Response rates among control subjects in case-control studies. Ann Epidemiol. 1995;5:245-249.
14. Edwards S, Slattery ML, Mon M, et al. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol. 1994;140:102-128.
15. Slattery ML, Caan B, Duncan D, et al. A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc. 1994;94:761-766.
16. Liu K, Slattery ML, Jacobs D, et al. A study of the reliability and comparative validity of the CARDIA dietary history. Ethn Dis. 1994;4:15-27.
17. Slattery ML, Boucher KM, Caan BJ, et al. Eating patterns and colon cancer. Am J Epidemiol. 1998;148:4-16.
18. Slattery ML, Edwards SL, Palmer L, et al. Use of archival tissue in epidemiologic studies: collection procedures and assessment of potential sources of bias. Mutat Res. 2000;432:7-14.
19. Spirio LN, Samowitz W, Robertson J, et al. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet. 1998;20:385-388.
20. Bonner MR, Ballard LW. Considerations in adding mutation detection services to a sequencing core facility. J Biomol Tech. 1999;10:177-186.
21. Baas IO, Mulder JR, Offerhaus GJ, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994;172:5-12.
22. Soong R, Robbins PD, Dix BR, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol. 1996;27:1050-1055.
23. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer. 1996;74:216-223.
24. Tolbert DM, Noffsinger AE, Miller MA, et al. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol. 1999;12:54-60.
25. Borresen-Dale AL, Lothe RA, Meling GI, et al. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res. 1998;4:203-210.
26. Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001;61:2505-2512.